{"generic":"Celecoxib","drugs":["CeleBREX","Celecoxib"],"mono":[{"id":"924848-s-0","title":"Generic Names","mono":"Celecoxib"},{"id":"924848-s-1","title":"Dosing and Indications","sub":[{"id":"924848-s-1-4","title":"Adult Dosing","mono":"<ul><li>before initiating treatment with celecoxib, weigh the potential benefits and risks of NSAIDs; other treatment options should be considered<\/li><li>to reduce the risk of serious adverse effects, use the lowest effective  dose of celecoxib for the shortest possible duration<\/li><li>after observing initial response, adjust dose and frequency to meet  individual patient's needs<\/li><li><b>Ankylosing spondylitis:<\/b> initial, 200 mg ORALLY once daily or 100 mg twice daily; if no effect occurs after 6 weeks, increase to 400 mg ORALLY daily; if no effect occurs after 6 weeks at 400 mg daily, then discontinue and consider alternative therapy<\/li><li><b>Gout, acute:<\/b> High dose: 800 mg orally immediately, followed by 400 mg 12 hours later and then 400 mg every 12 hours for 7 days<\/li><li><b>Osteoarthritis:<\/b> 100 mg ORALLY twice a day or 200 mg ORALLY once a day<\/li><li><b>Pain, acute:<\/b> initial dose, 400 mg ORALLY once plus one additional 200 mg dose ORALLY if needed on the first day; maintenance, 200 mg ORALLY twice a day as needed<\/li><li><b>Postoperative pain, acute:<\/b> 400 mg ORALLY postprocedure (study dosing)<\/li><li><b>Primary dysmenorrhea:<\/b> initial dose, 400 mg ORALLY once plus one additional 200 mg dose ORALLY if needed on the first day; maintenance, 200 mg ORALLY twice a day as needed<\/li><li><b>Rheumatoid arthritis:<\/b> 100 to 200 mg ORALLY twice a day<\/li><\/ul>"},{"id":"924848-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>before initiating treatment with celecoxib, weigh the potential benefits and risks of NSAIDs; other treatment options should be considered<\/li><li>to reduce the risk of serious adverse effects, use the lowest effective  dose of celecoxib for the shortest possible duration<\/li><li>after observing initial response, adjust dose and frequency to meet  individual patient's needs<\/li><li>safety and efficacy has been established only in children 2 years of age or older and for a maximum of 6 months of treatment in juvenile rheumatoid arthritis; safety and efficacy has not been established in children for any other indication<\/li><li><b>Juvenile rheumatoid arthritis:<\/b> (2 years or older) 10 to 25 kg, 50 mg ORALLY twice daily<\/li><li><b>Juvenile rheumatoid arthritis:<\/b> (2 years or older) greater than 25 kg, 100 mg ORALLY twice daily<\/li><\/ul>"},{"id":"924848-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, severe:<\/b> celecoxib is not recommended<\/li><li><b>hepatic impairment, moderate (Child-Pugh Class B):<\/b> reduce dosage by 50%<\/li><li><b>hepatic impairment, severe (Child-Pugh Class C):<\/b> celecoxib is not recommended<\/li><li><b>geriatrics:<\/b> weighing less than 50 kg, initiate therapy at the lowest recommended dosage<\/li><li><b>poor CYP2C9 metabolizers, known or suspected:<\/b> initiate therapy at half the lowest recommended dose<\/li><li><b>poor CYP2C9 metabolizers, juvenile rheumatoid arthritis:<\/b> consider using other therapy<\/li><\/ul>"},{"id":"924848-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Ankylosing spondylitis<\/li><li>Juvenile rheumatoid arthritis<\/li><li>Osteoarthritis<\/li><li>Pain, acute<\/li><li>Primary dysmenorrhea<\/li><li>Rheumatoid arthritis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Colorectal adenoma, Sporadic, High-risk patients; Prophylaxis<\/li><li>Coronary stent stenosis, Adjunct; Prophylaxis<\/li><li>Gout, acute<\/li><li>Postoperative pain, acute<\/li><\/ul>"}]},{"id":"924848-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule)<\/b><br\/>Celecoxib may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may be increased in patients with cardiovascular disease or risk factors for cardiovascular disease. Celecoxib is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. Celecoxib can also cause an increased risk of serious gastrointestinal adverse events especially in the elderly, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.<br\/>"},{"id":"924848-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924848-s-3-9","title":"Contraindications","mono":"<ul><li>asthma, urticaria, or allergic-type reaction following aspirin or other NSAID administration; severe and rarely fatal anaphylactic-like reactions have been reported<\/li><li>coronary artery bypass graft (CABG) surgery, treatment of perioperative pain<\/li><li>hypersensitivity to celecoxib or any component of the product<\/li><li>hypersensitivity to sulfonamides<\/li><\/ul>"},{"id":"924848-s-3-10","title":"Precautions","mono":"<ul><li>cardiovascular thrombotic events; myocardial infarction, stroke, and fatalities have been reported; risk may increase with duration of use<\/li><li>cardiovascular disease, known or risk factors for; increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke<\/li><li>elderly; increased risk of serious gastrointestinal adverse events (bleeding, ulceration, perforation of stomach or intestines) that can occur at any time and without warning<\/li><li>gastrointestinal adverse events; ulceration, bleeding, or perforation of stomach or intestines, potentially fatal may occur without warning; increased risk with concurrent use of aspirin, corticosteroids, and anticoagulants; monitoring recommended<\/li><li>anaphylactoid reactions and angioedema have occurred<\/li><li>aspirin triad (bronchospasm in asthmatic patients with rhinitis, with or without nasal polyps following aspirin or NSAID administration); risk of severe, potentially fatal bronchospasm; not recommended<\/li><li>asthma, preexisting; risk of severe and potentially fatal bronchospasm<\/li><li>concomitant use with other NSAIDs should be avoided<\/li><li>elderly; increased risk of renal toxicity or injury<\/li><li>fluid retention or heart failure; peripheral edema and fluid retention have been reported<\/li><li>gastrointestinal bleeding or history of ulcers, existing; increased risk of ulceration, bleeding, or perforation of stomach or intestines, potentially fatal<\/li><li>heart failure; increased risk of renal toxicity or injury<\/li><li>hepatic dysfunction, history; increased risk of renal toxicity and liver injury<\/li><li>hepatic impairment; not recommended in severe hepatic impairment and dose reduction required in moderate hepatic impairment<\/li><li>hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis, and hepatic failure, have been reported; discontinuation required for symptoms of or evidence of hepatic reactions<\/li><li>hypertension; development of HTN or worsening of HTN may occur; thiazides and loop diuretics may be less effective<\/li><li>longer duration of therapy; increased risk of potentially fatal gastrointestinal bleeding, ulceration, or perforation that may occur without warning and increased risk of renal papillary necrosis and other renal injury<\/li><li>pediatric use in patients with systemic onset juvenile rheumatoid arthritis; increased risk of disseminated intravascular coagulation<\/li><li>poor metabolizers of CYP2C9 substrates; decreased metabolism leading to high plasma levels; consider dosage adjustment or alternative therapy <\/li><li>poor general health status; increased risk of potentially fatal gastrointestinal bleeding, ulceration, or perforation that may occur without warning<\/li><li>pregnancy, third trimester; may cause premature closure of the ductus arteriosus<\/li><li>renal disease, advanced; use is not recommended<\/li><li>renal function, impaired; increased risk of renal toxicity or injury<\/li><li>renal papillary necrosis and other renal injury may occur; increased risk with concurrent use of ACE inhibitors, angiotensin II receptor antagonists, and diuretics<\/li><li>skin reactions; potentially fatal adverse events including exfoliative dermatitis, Stevens Johnson syndrome, and toxic epidermal necrolysis may occur<\/li><li>smoking or alcohol use; increased risk of potentially fatal gastrointestinal bleeding, ulceration, or perforation that may occur without warning<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"924848-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (1st trimester), C (2nd trimester), D (3rd trimester) (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"924848-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"924848-s-4","title":"Drug Interactions","sub":[{"id":"924848-s-4-13","title":"Contraindicated","mono":"<ul>Ketorolac (theoretical)<\/ul>"},{"id":"924848-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clopidogrel (probable)<\/li><li>Clovoxamine (probable)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Desirudin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Femoxetine (probable)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Methotrexate (theoretical)<\/li><li>Milnacipran (probable)<\/li><li>Nadroparin (probable)<\/li><li>Nefazodone (probable)<\/li><li>Nitisinone (theoretical)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Sibutramine (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Warfarin (probable)<\/li><li>Zimeldine (probable)<\/li><\/ul>"},{"id":"924848-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Arotinolol (probable)<\/li><li>Aspirin (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cilazapril (established)<\/li><li>Clopamide (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Fluconazole (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Lithium (probable)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perindopril (established)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>Talinolol (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},{"id":"924848-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (arthritis, 2.4%; familial adenomatous polyposis, 12.5%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (arthritis, 5.6%; familial adenomatous polyposis, 10.5%; juvenile rheumatoid arthritis, 4% to 5%), Nausea (arthritis, 3.5%; familial adenomatous polyposis, 6.8%; juvenile rheumatoid arthritis, 4% to 7%)<\/li><li><b>Neurologic:<\/b>Headache (arthritis, 15.8%; juvenile rheumatoid arthritis, 10% to 13%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction (arthritis, 0.1% to 1.9%), Torsades de pointes, Ventricular hypertrophy (familial adenomatous polyposis, 0.1% to 1%)<\/li><li><b>Dermatologic:<\/b>Erythema multiforme (arthritis, less than 0.1%), Erythroderma (arthritis, less than 0.1%), Stevens-Johnson syndrome (arthritis, less than 0.1%), Toxic epidermal necrolysis (arthritis, less than 0.1%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (arthritis, less than 0.1%), Gastrointestinal perforation (less than 0.1%), Gastrointestinal ulcer, Inflammatory disorder of digestive tract<\/li><li><b>Hematologic:<\/b>Thrombosis (familial adenomatous polyposis, 1.2%)<\/li><li><b>Hepatic:<\/b>Fulminant hepatitis (rare), Increased liver function test (0.1% to 1.9%), Liver failure (rare)<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction (arthritis, less than 0.1%)<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><li><b>Renal:<\/b>Acute renal failure, Interstitial nephritis (arthritis, less than 0.1%)<\/li><li><b>Respiratory:<\/b>Bronchospasm (arthritis, 0.1% to 1.9%)<\/li><li><b>Other:<\/b>Angioedema (arthritis, less than 0.1%)<\/li><\/ul>"},{"id":"924848-s-6","title":"Drug Name Info","sub":{"0":{"id":"924848-s-6-17","title":"US Trade Names","mono":"CeleBREX<br\/>"},"2":{"id":"924848-s-6-19","title":"Class","mono":"<ul><li>Analgesic<\/li><li>Cyclooxygenase-2 Inhibitor<\/li><\/ul>"},"3":{"id":"924848-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924848-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"924848-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic therapeutic effects. It has been proposed that celecoxib inhibits the activity of the enzyme cyclooxygenase-2 (COX-2), resulting in a decreased formation of precursors of prostaglandins. However, unlike most NSAIDs, celecoxib does not inhibit cyclooxygenase-1 (COX-1) isoenzyme in humans at therapeutic concentrations.<\/li><li>Celecoxib has anti-inflammatory and antipyretic actions that, together with its analgesic effects, may mask the onset and\/or progression of an infection.<\/li><\/ul>"},{"id":"924848-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"924848-s-8-23","title":"Absorption","mono":"Systemic: Rapid <br\/>"},"2":{"id":"924848-s-8-25","title":"Metabolism","mono":"Systemic: Hepatic: Via cytochrome P450 C9 pathway <br\/>"},"3":{"id":"924848-s-8-26","title":"Excretion","mono":"<ul><li>Systemic: Celecoxib- Fecal: 57%; Renal 27%, less than 3% unchanged<\/li><li>Carboxylic acid metabolite- Fecal\/Renal: 73% of dose<\/li><\/ul>"},"4":{"id":"924848-s-8-27","title":"Elimination Half Life","mono":"Systemic: 11 hr <br\/>"}}},{"id":"924848-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>doses up to 200 mg twice daily can be given with or without food<\/li><li>higher doses (400 mg twice daily) should be given with food to improve absorption<\/li><li>contents of capsules may be added to 1 level teaspoon of applesauce and ingested immediately with water; mixture is stable for up to 6 hours if refrigerated (2 to 8 degrees C or 35 to 45 degrees F)<\/li><\/ul>"},{"id":"924848-s-10","title":"Monitoring","mono":"<ul><li>acute pain\/dysmenorrhea: relief of pain<\/li><li>rheumatoid arthritis: improved range of motion, decreased early morning stiffness and painful\/swollen joints, C-reactive protein levels, erythrocyte sedimentation rate<\/li><li>familial adenomatous polyposis: colonoscopy<\/li><li>CBC, chemistry profile, blood pressure, fecal occult blood test, liver function; after initiation of NSAID therapy and every 6-12 months thereafter, more frequently in patients at risk for hepatic, renal, cardiac, or gastrointestinal toxicity (eg, age greater than 60 years, high-dose NSAID therapy, concurrent corticosteroids or anticoagulants, history of cardiac, renal, or hepatic disease)<\/li><li>hemoglobin, hematocrit; in patients with signs\/symptoms of anemia<\/li><li>signs and symptoms of skin reaction<\/li><\/ul>"},{"id":"924848-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Capsule: 50 MG, 100 MG, 200 MG, 400 MG<\/li><li>  Powder: 98 %<\/li><\/ul><\/li><li><b>CeleBREX<\/b><br\/>Oral Capsule: 50 MG, 100 MG, 200 MG, 400 MG<br\/><\/li><\/ul>"},{"id":"924848-s-12","title":"Toxicology","sub":[{"id":"924848-s-12-31","title":"Clinical Effects","mono":"<b>COX-2 INHIBITORS<\/b><br\/>USES: Cyclooxygenase-2 (COX-2) inhibitors are nonsteroidal anti-inflammatory drugs (NSAIDs), antipyretics, analgesics, and inhibitors of thrombocyte aggregation. Celecoxib (Celebrex) is used to treat rheumatoid arthritis and osteoarthritis and is the only remaining COX-2 inhibitor on the market in the US. Rofecoxib (Vioxx) was voluntarily removed from the market in 2004 due to concerns for increased risk of myocardial infarction and stroke, and valdecoxib (Bextra) was removed in 2005 for similar reasons. Etoricoxib (Arcoxia), lumiracoxib (Prexige), and parecoxib (Dynastat) [a prodrug of valdecoxib] are not approved for use in the US, but are available in other countries. PHARMACOLOGY: The cyclooxygenase (COX) enzyme (prostaglandin synthase H) consists of 2 isoforms, COX-1 and COX-2. COX-2 inhibitors decrease the synthesis of prostaglandin H2 by selectively inhibiting COX-2 (from 30- to 433-fold more potent towards COX-2 in vitro) with little or no inhibition of COX-1 at therapeutic doses. Although similar to traditional NSAIDs, selective inhibition of COX-2 may result in fewer gastrointestinal adverse effects usually associated with NSAIDs. TOXICOLOGY: At supratherapeutic doses, selective inhibition of COX-2 is lost, and the usual COX-1 effects may manifest in the GI tract as gastritis, and in the renal system as hypertension, decreased renal perfusion, decreased glomerular filtration rate, edema, and interstitial nephritis. EPIDEMIOLOGY: COX-2 inhibitors are an uncommon cause of poisoning, are usually unintentional, and rarely result in severe manifestations. OVERDOSE:  Little data are available. Significant poisonings result in symptoms similar to those observed with typical NSAIDs, such as GI upset, vomiting, abdominal pain. Rarely, hypertension, acute renal failure, respiratory depression, drowsiness, dizziness, confusion, and coma may occur. ADVERSE EFFECTS: COMMON: GI effects occur most commonly and include dyspepsia, nausea, diarrhea, abdominal pain, pancreatitis, and flatulence. Other fairly common findings include headache and fever. SEVERE: Celecoxib is rarely associated with cardiac or renal events. GI bleeding may occur with chronic use. Methemoglobinemia is a rare event. Rofecoxib was voluntarily withdrawn from the market in 2004, due to an increased risk of severe dysrhythmias (ventricular fibrillation, cardiac arrest and sudden death), renal events, and associated with aseptic meningitis.<br\/>"},{"id":"924848-s-12-32","title":"Treatment","mono":"<b>COX-2 INHIBITORS <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Most exposures are mild and require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Support respiratory and cardiovascular function as needed. GI hemorrhage is a possibility and can be managed supportively with standard treatment measures.<\/li><li>Decontamination: PREHOSPITAL: Generally no decontamination is needed. HOSPITAL: Overdose is unlikely to cause severe intoxication, so activated charcoal is likely unnecessary. It can be used for worrisome coingestants.<\/li><li>Airway management: Provide supportive care as this is not likely to be an issue.<\/li><li>Antidote: There is no antidote available.<\/li><li>Monitoring of patient: Monitor serum electrolytes, renal function and urinalysis after significant overdose. Obtain acetaminophen and salicylate concentrations, if there is any uncertainty of the drug ingested or if the overdose was intentional. Laboratory studies are generally unnecessary, since COX-2 overdose patients manifest mild signs and symptoms. Specific drug concentrations are not helpful.<\/li><li>Enhanced elimination procedure: There is no role for hemodialysis given the high degree of protein binding and very large volume of distribution.<\/li><li>Patient disposition: HOME CRITERIA: Patients with unintentional ingestions may be observed at home if asymptomatic. OBSERVATION CRITERIA: Symptomatic patients with uncontrollable nausea, vomiting, or abdominal pain should be evaluated in a healthcare facility. Once a patient is asymptomatic for 6 hours, they may be discharged. Patients with a deliberate self-harm attempt should be evaluated in a healthcare facility. ADMISSION CRITERIA: Symptomatic patients requiring ongoing supportive care may need to be admitted. Once a patient is asymptomatic for 6 hours, they may be discharged. CONSULT CRITERIA: Severe poisoning does not usually occur with COX-2 inhibitors. Consult a medical toxicologist if uncertain about drug effects.<\/li><\/ul>"},{"id":"924848-s-12-33","title":"Range of Toxicity","mono":"<b>COX-2 INHIBITORS<\/b><br\/>TOXICITY: Overdose information is limited. In a series of celecoxib-only ingestions in children aged 0 to 5 years, 92 patients ingested a reported mean dose of 305.5 mg (range: 10 to 2300 mg), while the dosage ingested in 46 patients was reported in mg\/kg with a mean ingested dose of 29.22 mg\/kg (range 1.38 to 186.99 mg\/kg). Most (96.6%) children developed no symptoms. The most frequently reported adverse effects included: drowsiness, agitation, vomiting, abdominal pain, and rash. However, these events were observed in less than 2% of the cases. THERAPEUTIC DOSE: CELECOXIB: ADULT: Therapeutic dosing is 100 to 200 mg once or twice daily for osteoarthritis and rheumatoid arthritis, and 400 mg initially for analgesia. PEDIATRIC: Dosing for Juvenile Rheumatoid Arthritis is 50 mg twice daily for children weighing 10 to 25 kg, and 100 mg twice daily for children greater than 25 kg. <br\/>"}]},{"id":"924848-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to seek immediate medical attention for symptoms of anaphylaxis. Severe anaphylactic\/anaphylactoid reactions, some fatal, have been reported.<\/li><li>This drug may cause peripheral edema, abdominal pain, diarrhea, dyspepsia, flatulence, nausea, back pain, dizziness, headache, insomnia, pharyngitis, rhinitis, sinusitis, upper respiratory infection, or cerebrovascular accident.<\/li><li>Instruct patients to report signs\/symptoms of gastrointestinal adverse events (bleeding, ulceration, perforation of stomach or intestines). Elderly and debilitated patients are particularly at risk.<\/li><li>Counsel patients to report signs\/symptoms of cardiovascular thrombotic events, such as a myocardial infarction or stroke, and to monitor for changes in blood pressure.<\/li><li>Advise patients to report signs\/symptoms of anemia or a skin reaction.<\/li><li>Instruct patients on higher doses (400 mg twice daily) to take drug with food. Lower doses may be taken with or without food.<\/li><li>Tell patient to avoid drinking alcohol and smoking, as this may increase risk for gastrointestinal bleeding<\/li><li>Advise patient to not use any other NSAID medications during celecoxib therapy, unless approved by healthcare professional.<\/li><\/ul>"}]}